RhumbLine Advisers’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
Other funds holding IRMD
CCM
VCM
NTCM
RhumbLine Advisers's IRMD Position: Q1 2026 in Review
RhumbLine Advisers reduced its iRadimed (IRMD) stake by 0.65% in Q1 2026, selling an estimated $8.9K and leaving 13,503 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2067.
RhumbLine Advisers first reported a position in IRMD in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.32M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- RhumbLine Advisers held 13,503 shares of iRadimed worth $1.3M as of Q1 2026.
- RhumbLine Advisers sold 89 iRadimed shares in Q1 2026, an estimated $8.9K.
- iRadimed made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2067 holding.
- RhumbLine Advisers first reported a position in iRadimed in Q4 2021 and has held it in 18 quarters since.
- RhumbLine Advisers's iRadimed position peaked at $1.32M in Q4 2025.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.